Article Abstract

Enzalutamide (formerly MDV3100) prolongs survival in docetaxel-pretreated castration-resistant prostate cancer patients

Authors: Matthias M. Heck, Jürgen E. Gschwend, Margitta Retz


Until lately, castration-resistant prostate cancer (CRPC) patients who progressed following docetaxel chemotherapy had no treatment alternative with proven survival benefit. This changed with a series of recently published phase III trials that lead to approval of several new, life-prolonging agents by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA).


  • There are currently no refbacks.